FSGS
Conditions
Keywords
FSGS, suPAR
Brief summary
The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.
Interventions
None listed
Sponsors
Guangdong Provincial People's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
14 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Age at entry is between 14 and 70 years * biopsy-proven primary FSGS * proteinuria \>=3 g/day * without corticosteroids or CsA treatment before entry
Exclusion criteria
* Chronic Inflammatory Diseases * malignant tumor * diabetes mellitus * contraindications for the treatment of corticosteroids or CsA treatment * untolerate to or unwilling to accept corticosteroids or CsA treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| serum suPAR level when proteinuria reduction >=50% or complete remission | 6 months after steriod alone or CsA plus steriod treatment | serum suPAR level when proteinuria reduction of \>=50% or complete remission occurs within \<=6 months of steroid alone or CsA plus steroid treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| serum suPAR level after 6 months of steroid or CsA treatment without remission | 6 months after steroid alone or CsA plus steroid treatment | serum suPAR level after 6 months of steroid alone or CsA plus steroid treatment without remission |
Countries
China
Contacts
Primary ContactWei Shi, MD,PhD
Outcome results
None listed